Research by Dr Karen Chung

All of our attendees carry out a piece of research in an area of MS clinical practice or treatment that interests them.

This project was awarded runner up in the MS Academy MasterClass Project Awards Autumn 2018, and this snapshot gives you a quick idea of what Dr Chung found and why. If you want to learn more, just click through to her full slide set, or follow the links within the snapshot.

If you would like to contact the Dr Chung, drop us a line and we’ll put you in touch where possible.

 

Aim

The three-part objective was:

  • To estimate the number of people living with primary-progressive multiple sclerosis (PPMS) in the researcher’s department,
  • to consider the number who may potentially meet the eligibility criteria for Ocrelizumab and
  • to create service plans to support roll out of the drug, if licensed.

Headlines

Key findings

  • Findings were gathered via retrospective review of MS clinic notes from Jan-March 2018 and a review of all available electronic clinical notes.
  • Of 1082 MS clinic visits, 52 patients had PPMS
  • Using eligibility criteria expected across age, EDSS, and disease duration, a potential 40 patients were estimated likely eligible for treatment.

Core recommendations

  • Prepare for the potential increase in PPMS referrals.
  • Await NICE recommendations (due 31 October 2018).

 

Take action